Literature DB >> 25228532

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

Katerina Politi1, Scott Gettinger2.   

Abstract

Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25228532      PMCID： PMC4401422          DOI： 10.1158/1078-0432.CCR-14-2306

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors:  Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

2.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Authors:  Luc Friboulet; Nanxin Li; Ryohei Katayama; Christian C Lee; Justin F Gainor; Adam S Crystal; Pierre-Yves Michellys; Mark M Awad; Noriko Yanagitani; Sungjoon Kim; AnneMarie C Pferdekamper; Jie Li; Shailaja Kasibhatla; Frank Sun; Xiuying Sun; Su Hua; Peter McNamara; Sidra Mahmood; Elizabeth L Lockerman; Naoya Fujita; Makoto Nishio; Jennifer L Harris; Alice T Shaw; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2014-03-27       Impact factor: 39.397

3.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

4.  Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Authors:  Christine M Lovly; William Pao
Journal:  Sci Transl Med       Date:  2012-02-08       Impact factor: 17.956

Review 5.  ALK in lung cancer: past, present, and future.

Authors:  Alice T Shaw; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

6.  Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.

Authors:  Sai-Hong Ignatius Ou; Michele Azada; David J Hsiang; June M Herman; Tatiana S Kain; Christina Siwak-Tapp; Cameron Casey; Jie He; Siraj M Ali; Samuel J Klempner; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609

7.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

8.  Identification of ALK as a major familial neuroblastoma predisposition gene.

Authors:  Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

9.  Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Authors:  Ryohei Katayama; Luc Friboulet; Sumie Koike; Elizabeth L Lockerman; Tahsin M Khan; Justin F Gainor; A John Iafrate; Kengo Takeuchi; Makoto Taiji; Yasushi Okuno; Naoya Fujita; Jeffrey A Engelman; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2014-09-16       Impact factor: 12.531

10.  Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

Authors:  Sen Zhang; Frank Wang; Jeffrey Keats; Xiaotian Zhu; Yaoyu Ning; Scott D Wardwell; Lauren Moran; Qurish K Mohemmad; Rana Anjum; Yihan Wang; Narayana I Narasimhan; David Dalgarno; William C Shakespeare; Juan J Miret; Tim Clackson; Victor M Rivera
Journal:  Chem Biol Drug Des       Date:  2011-10-31       Impact factor: 2.817
  10 in total
  3 in total

1.  Lung cancer in the era of precision medicine.

Authors:  Katerina Politi; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 2.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

Review 3.  Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.

Authors:  Ravi Salgia
Journal:  Expert Rev Mol Diagn       Date:  2016-05-26       Impact factor: 5.225
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.